Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16
We collaborate with multiple shipping carriers based on the delivery location
This shuts down the bodys natural production through a negative feedback loop
Given the high prevalence of fatty liver in diabetic patients (estimated at 5570%), initiating or switching to a GLP-1 agonist addresses both conditions simultaneously
Myricetin functions as a glucose-dependent insulin secretagogue, akin to GLP-1 and includes the inhibition of beta cell apoptosis, glucoregulation and the prevention of hypoglycemia
Last year (2025), Novo Nordisk had sought to further position itself in the obesity drug market with a bid to acquire Metsera, a New York-based clinical-stage bio/pharmaceutical company focused on obesity and cardiometabolic diseases, eventually losing a bidding war with Pfizer, which acquired Metsera last November (November 2025) in a deal worth up to $11 billion
.jpg)